Systemic Sclerosis Interstitial Lung Disease (SSc-ILD): Optimizing Treatment Strategies

Systemic Sclerosis Interstitial Lung Disease (SSc-ILD): Optimizing Treatment Strategies is organized by ScientiaCME.

Release Date: Aug 20, 2018
Expiration Date: Aug 20, 2020

Accreditation:
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Pharmacists:
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hours (0.1 CEUs) of continuing education. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE # 0574-0000-18-026-H01-P. ACPE Accreditation effective 08/20/18 expires 08/20/20. This is a Knowledge (K)-type activity. 

Description:
In this online CME self-learning program:
Systemic sclerosis (SSc) is a rare connective tissue disease that affects 276 people per million in the U.S., of whom around 70% will experience interstitial lung disease (ILD). The disease is characterized by a progressive course of scarring to the blood vessels underlying the skin, connective tissue, joints, and organs. The pathology of SSc remains to be fully elucidated, but different immunologic and genetic pathways have been explored as potential precipitating factors for SSc. Based on what is known, SSc-ILD may be summarized into three steps: 1) continuous injury to endothelial cells, 2) activation of innate and adaptive immunity, 3) recruitment and activation of fibroblasts.

Objectives:
By the end of the session the participant will be able to:
• Describe the etiology of SSc-ILD and its impact on patient clinical presentation and available pharmacotherapeutic treatments
• Describe the prevalence, clinical features, and presentation of SSc-ILD
• Evaluate treatments plans for SSc-ILD patients and suggest appropriate therapies, where applicable, based on individual presentations
• Describe present and emerging drug therapies for management of SSc-ILD and apply them to patient cases taking into account the patient?s history
• Describe clinical and logistical challenges associated with treating and educating patients with SSc-ILD